| Literature DB >> 12069645 |
David B McAdam1, Jennifer R Zarcone, Jessica Hellings, Deborah A Napolitano, Stephen R Schroeder.
Abstract
Consumer satisfaction and social validity were measured during a double-blind, placebo-controlled evaluation of the atypical neuroleptic risperidone in treating severe aberrant behavior of persons with developmental disabilities. First, a satisfaction survey was completed after a medication trial by each participant's caregiver. Results showed that 100% of the caregivers felt that participation was a positive experience for themselves and participants. Second, 52 community members viewed videotapes of 5 participants during a clinical interview when they were taking either placebo or risperidone. Raters also indicated that when on the medication, participants displayed fewer aberrant behaviors, were less irritable, in a better mood, and were more responsive to their environment.Entities:
Mesh：
Substances：
Year: 2002 PMID： 12069645 DOI： 10.1352/0895-8017(2002)107<0261:EOROAB>2.0.CO;2
Source DB: PubMed Journal: Am J Ment Retard ISSN： 0895-8017